Physician profile
Stephanie Stringfield
NPI 1356613293
$2,811.23
in general payments reported to CMS, 2019-2025
31 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $786 · 2022: $1,132 · 2023: $440 · 2024: $350 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.16 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $680.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $196.32 | 2021-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $189.21 | 2021-2022 | |
| Lilly USA, LLC | $171.69 | 2021-2024 | Mounjaro, Zepbound |
| Si-Bone, INC. | $156.98 | 2022 | |
| Amgen INC. | $146.49 | 2021-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.24 | 2022-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $129.24 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.71 | 2021-2022 | |
| Astellas Pharma US INC | $100.05 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $97.17 | 2021-2024 | Trelegy Ellipta |
| Pfizer INC. | $90.90 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.99 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $83.79 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $57.57 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $57.49 | 2021-2022 | |
| Exact Sciences Corporation | $53.72 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $38.41 | 2025 | Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.48 | 2022 | |
| Sanofi Pasteur INC. | $25.30 | 2021-2022 | |
| Philips North America LLC | $23.92 | 2024 | (Ck7) Extended Holter |
| Esperion Therapeutics, INC. | $20.24 | 2021 | |
| Daiichi Sankyo INC. | $18.86 | 2024 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $18.64 | 2022 | |
| Upsher-Smith Laboratories LLC | $18.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.15 | 2022 | |
| Abbott Laboratories | $15.12 | 2023 | Proclaim |
| Biodelivery Sciences International, INC. | $14.30 | 2021 | |
| Organon LLC | $14.03 | 2022 | |
| Roche Diagnostics Corporation | $12.80 | 2021 | |
| Eisai INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Stringfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.